Favorable News Coverage Very Unlikely to Impact CRH Medical (CRM) Stock Price

Media coverage about CRH Medical (CVE:CRM) has been trending positive on Saturday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than 6,000 news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CRH Medical earned a news sentiment score of 2.78 on their scale. InfoTrie also gave press coverage about the company an news buzz score of 2 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company’s share price in the immediate future.

CRM stock traded down C$2.14 during mid-day trading on Friday, reaching C$119.26. 1,671,836 shares of the company’s stock were exchanged, compared to its average volume of 5,832,858. CRH Medical has a 12-month low of C$83.00 and a 12-month high of C$128.87.

WARNING: “Favorable News Coverage Very Unlikely to Impact CRH Medical (CRM) Stock Price” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/11/10/favorable-news-coverage-very-unlikely-to-impact-crh-medical-crm-stock-price.html.

About CRH Medical

CRH Medical Corporation (CRH) specializes in the distribution of medical products directly to physicians, particularly those in the gastroenterologist community. The Company’s lead product, the CRH O’Regan System, is a single use, disposable, hemorrhoid treatment that is used in treating hemorrhoid grades I-IV.

Featured Story: Swap

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply